GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanologica AB (OSTO:NICA) » Definitions » Loans Receivable

Nanologica AB (OSTO:NICA) Loans Receivable : kr0.00 Mil (As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is Nanologica AB Loans Receivable?

Nanologica AB's Loans Receivable for the quarter that ended in Mar. 2025 was kr0.00 Mil.


Nanologica AB Loans Receivable Historical Data

The historical data trend for Nanologica AB's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanologica AB Loans Receivable Chart

Nanologica AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Nanologica AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Nanologica AB Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Nanologica AB Loans Receivable Related Terms

Thank you for viewing the detailed overview of Nanologica AB's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Nanologica AB Business Description

Traded in Other Exchanges
N/A
Address
Forskargatan 20 G, Sodertalje, SWE, SE-151 36
Nanologica AB is engaged in the production and sales of silica-based chromatography products. The company develops and manufactures nanoporous silica particles for life science applications. The company's drug delivery platforms are NLAB Spiro, NLAB Silica, and others, which focus on producing medicines for the benefit of patients. Its geographical segments are China, India, the United States, and the Rest of the world.

Nanologica AB Headlines

No Headlines